PK Stat analysis for Levothyroxine sodium studies for USFDA submission [Design Issues]

posted by jag009  – NJ, 2017-10-24 07:45 (3170 d 04:15 ago) – Posting: # 17909
Views: 4,199

Hi,

❝ OGD is not mentioned about exclusion of subjects from Pharmacokinetic and statistical analysis, after baseline correction if subject having more-than 5% of Cmax on pre-dose concentration. This criteria we can apply for endogenous products or not?


Why now? Theoretically speaking after baseline correction the amount of drug in the system is "ought" to be attributed to the drug products.

J

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
126 visitors (0 registered, 126 guests [including 16 identified bots]).
Forum time: 12:00 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5